SPX3,831.39+6.06 0.16%
DIA309.71-1.14 -0.37%
IXIC11,322.24+194.39 1.75%

BRIEF-New Imbruvica Data In Fixed-Duration Combination Regimen Presented At Eha 2022 Shows Deep, Durable Response At Three Years In Untreated Chronic Lymphocytic Leukemia

reuters.com · 06/10/2022 08:42
BRIEF-New Imbruvica Data In Fixed-Duration Combination Regimen Presented At Eha 2022 Shows Deep, Durable Response At Three Years In Untreated Chronic Lymphocytic Leukemia

- Johnson & Johnson JNJ:

  • NEW IMBRUVICA® (IBRUTINIB) DATA IN FIXED-DURATION COMBINATION REGIMEN PRESENTED AT EHA 2022 SHOWS DEEP, DURABLE RESPONSE AT THREE YEARS IN UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA

Source text for Eikon: ID:nPn73PcX3a

Further company coverage: JNJ


((reuters.briefs@thomsonreuters.com;))